A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer
Interventions: DRUG: AZD9833
Sponsor: AstraZeneca